73907-98-9

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 6-amino-1H-indazole-7-carboxylate is utilized as a key intermediate in the synthesis of pharmaceutical compounds for various therapeutic applications. Its unique structure and properties make it a promising candidate for the development of new drugs, particularly those targeting inflammation and pain.
Used in Chemical Research:
In the realm of chemical research, Methyl 6-amino-1H-indazole-7-carboxylate is employed as a building block for the creation of novel organic compounds. Its versatility in chemical reactions allows for the exploration of new chemical entities with potential applications in various fields.
Used in Medicinal Property Studies:
Methyl 6-amino-1H-indazole-7-carboxylate is studied for its potential medicinal properties, such as its anti-inflammatory and analgesic effects. Research in this area aims to uncover its therapeutic potential and contribute to the development of effective treatments for inflammatory and painful conditions.
Used in Drug Development:
As a promising candidate for drug development, Methyl 6-amino-1H-indazole-7-carboxylate is integral to the process of discovering and creating new pharmaceuticals. Its role in this process is to provide a foundation for the design and synthesis of innovative drugs that can address a wide array of medical conditions.

Upstream product

• 6967-12-0 6-amino-1H-indazole 
• 73907-93-4 2-[(E)-Hydroxyimino]-N-(1H-indazol-6-yl)-acetamide 
• 73907-93-4 6-(isonitrosoacetamido)indazole 
• 77929-34-1 6-(hydroximinoacetyl)-amino-1H-indazole hydrochloride 
• 73907-94-5 pyrrolo<2,3-g>indazole-7,8-dione 
• 186581-53-3 diazomethane 
• 73907-95-6 6-aminoindazole-7-carboxylic acid 

Downstream Products

• 154597-37-2 6-amino-7-indazolecarboxaldehyde 
• 73907-90-1 prox-benzoisoallopurinol 

Relevant academic research and scientific papers

PESTICIDES CONTAINING A BICYCLIC BISAMIDE STRUCTURE

Compounds of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.

ANTITUMOR AGENTS. VI. SYNTHESIS AND ANTITUMOR ACTIVITY OF RING A-, RING B-, AND RING C-MODIFIED DERIVATIVES OF CAMPTOTHECIN

Eleven ring A-, ring B-, and ring C-modified analogues of the antitumor alkaloid camptothecin (1) were prepared and evaluated for cytotoxicity and antitumor activity against P388 mouse leukemia.Among the six ring A-modified analogues, hexacyclic compound (14) retained the same order of activity as 1.Most of the ring B- and ring C-modified analogues displayed greatly reduced activity, whereas compound (39), which has an alkylidene group at position 5, was found to be as active as 1.These results confirmed the necessity of the intact rings A, B, and C of 1 for antitumor activity.Further, the higher activity of 14 and 39 suggest that the"northern" part of the camptothecin molecule may be a suitable site for functionalization to obtain more potent analogues of 1.

SYNTHESIS OF A -LINKED PYRAZOLOQUINAZOLINONE

A convenient synthesis is described for pyrazoloquinazolin-9-one (4), an internally expanded benzolog of the biologically relevant pyrazolopyrimidines (2).

Synthesis of prox-Benzoisoallopurinol

Pyrazoloquinazolin-9-one (prox-benzoisoallopurinol, 1), an extented analogue of 7-hydroxypyrazolopyrimidine (isoallopurinol, 2) and a potential dimensional probe for substrates of xanthine oxidase, has been synthesized by two independent routes.The title compound, prepared by elaboration of either a suitably substituted indazole or a quinazolinone, was found to be an active substrate for and an alternative-substrate inhibitor of xanthine oxidase.The product of enzymatic oxidation of prox-benzoisoallopurinol has been identified as the corresponding prox-benzoisoalloxanthine.

Quinazoline derivatives

Novel quinazoline derivatives of the formula (1) STR1 wherein ring C is a pyrazole ring fused to ring B in two vicinal positions thereof that are not fused with ring A. The novel formula (1) compounds or pyrazolo-quinazoline-ones are structurally related to allopurinol, a well known drug useful in the treatment of gout and are expected to replace or complement allopurinol in the therapeutic use thereof. The generic name Benzoallopurinol is suggested for the novel formula (1) compounds; formula (1) includes angular and linear structures of the interfused rings A, B and C. Two methods for producing the novel formula (1) compounds are disclosed. The first method starts from the indazole structure that includes the interfused rings B and C, and ring A is formed on the indazole moiety. The second method starts from the quinazoline structure that includes interfused rings A and B, and the pyrazole ring C is formed on the benzo moiety (ring B) of the quinazoline structure. Either method may lead to angular or linear benzoallopurinols depending upon the substituents introduced into the starting structure for forming the complemental ring thereon.